Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02432729 · ClinicalTrials.gov registry record
A Smoking Cessation Study to Understand the Biological and Functional Changes After One Year of Smoking Cessation
A clinical trial, sponsored by Philip Morris Products S.A..
- Completed
- Registry status
- 1,184
- Enrollment target
NCT02432729: Completed study, sponsored by Philip Morris Products S.A..
NCT02432729 is a clinical trial that has completed, run by Philip Morris Products S.A.. The registered enrollment target is 1,184 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02432729 has completed, sponsored by Philip Morris Products S.A..
- COMPLETED
- Registry status
- 1,184 participants
- Enrollment target
Study Summary
The purpose of this study was to understand the biological and functional changes after one year of smoking cessation and to collect data on a broad range of biomarkers of exposure (BoExp) and biomarkers of effect (BoE).
Primary Outcome
Concentrations of HDL-C measured in serum. Mean values are provided as descriptive statistics.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,184 participants |
| Start Date | 2015-05-05 |
| Est. Completion | 2018-04-27 |
What the finished NCT02432729 record still lists
NCT02432729 is an observational study that tracks outcomes without assigning an intervention. Its 1,184 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02432729 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02432729 about?
NCT02432729 is a clinical study titled "A Smoking Cessation Study to Understand the Biological and Functional Changes After One Year of Smoking Cessation". The purpose of this study was to understand the biological and functional changes after one year of smoking cessation and to collect data on a broad range of biomarkers of exposure (BoExp) and biomarkers of effect (BoE).
What is the current status of trial NCT02432729?
This trial is currently completed. The enrollment target is 1,184 participants. The study started on 2015-05-05. Estimated completion is 2018-04-27.
Who is sponsoring clinical trial NCT02432729?
This trial is sponsored by Philip Morris Products S.A., which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04293562 · 1,186 participants · Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- NCT07286058 · 1,182 participants · Phase 3
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
- NCT05580419 · 1,188 participants · NA
Impact of 4PCP on Practitioner and Patient Outcomes
- NCT06290869 · 1,188 participants · Phase 3
Tobacco Education and Lung Health Study (TEAL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI